Affymax (AFFY) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)
Depreciation and amortization	0
Amortization of discount/premium on investments	0
Stock-based compensation expense	781K
Gain on disposal of property and equipment	0
Receivable from Takeda	0
Income taxes receivable
Prepaid expenses and other current assets	-330K
Other assets
Accounts payable	-21K
Accrued liabilities	-447K
Accrued clinical trial expenses	0
Payable to Takeda
Deferred revenue
Long-term income tax liability
Other long-term liabilities
Net cash used in operating activities
Purchases of property and equipment
Purchases of investments
Proceeds from sales of investments
Proceeds from maturities of investments	0
Proceeds from sale of property and equipment	0
Net cash provided by (used in) investing activities
Proceeds from issuance of common stock upon exercise of stock options	0
Proceeds from issuance of common stock under employee stock purchase plan
Proceeds from common stock issued upon public offering, net of issuance cost
Repayment of UBS loan
Net cash provided by (used in) financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of the period	5.6M
Cash and cash equivalents at end of the period	3.4M

Entities mentioned with AFFY

View All Entities